Pharmacielo Ltd. · TSXV:PCLO
Pharmacielo — Investor Presentation (February 2024)
14 slides from Pharmacielo's investor presentation, February 2024
Slide 1: The World’s Partner in Medicinal Cannabis
The World’s Partner in Medicinal Cannabis TSXV: PCLO, OTCQX: PCLOF | Feb 2024
Slide 2: Forward-looking Statements
Forward-looking Statements This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company. This Presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or advert
Slide 3: PharmaCielo Highlights
PharmaCielo Highlights • The next large opportunity in cannabis is on the global supply chain – B2B supply requirements are PharmaCielo’s 2000 m2 facility and 30 acres of cultivation position it as a world leader in quality, consistency and scale emerging, with very few global players to fill the mar
Slide 4: PharmaCielo high-efficiency at large-scale production
PharmaCielo high-efficiency at large-scale production. Colombia’s all-year 12-hour photoperiod, Rionegro cultivation facility does not consistent temperatures, rich soil, ample require costly climate-controlled water – are ideal for premium cannabis greenhouses, providing a significant quality and p
Slide 5: Advanced Genetics for Stable, Consistent Flower
Advanced Genetics for Stable, Consistent Flower PharmaCielo boasts one of the world’s only The Company is capable of delivering very advanced tissue and culture labs dedicated to specific profiles of cannabinoids and terpenes the in vitro propagation and long-term that respond to the needs of specific
Slide 6: Pharma approach for consistent quality: GACP
Pharma approach for consistent quality: GACP PharmaCielo is built to be a reliable long-term supply partner for large producers around the world In the north of Colombia’s Cauca region, the Andean slopes gently descend to meet the Pacific Ocean. This unique landscape, today home to thriving sugar can
Slide 7: Pharma approach for consistent quality: GACP
Pharma approach for consistent quality: GACP Our cultivar 1008 is a variety derived from Hashplant. High in THC with a shorter period of growth. It stands from other cannabis varieties due to its deep, rich Afghan aroma that is underscored with a herbal touch. CANNABINOID PROFILE FULL TERPENE BREAKD
Slide 8: Pharma approach for consistent quality: EUGMP compliant for extracts
Pharma approach for consistent quality: EUGMP compliant for extracts with a broad range of products and capacity to deliver be spoke formulations PharmaCielo’s goal of supplying global phyto- pharmaceutical producers with cannabis flower and extracts in the most consistent, safe and sustainable Full
Slide 9: The Colombia Advantage
The Colombia Advantage: Colombia offers a unique mix of advantages that make it a perfect location for a modern, global cannabis export industry. Colombia’s strong regulatory support for the medical cannabis export industry is only part of the reason why the country is a uniquely advantageous locat
Slide 10: Led by Experience
Led by Experience Marc Lustig Ian D. Atacan Andrés Felipe Botero Ana Restrepo Chairman and Chief Executive Officer CFO, Corporate Secretary and Director Chief Operating Officer Head of Business Development Marc founded CannaRoyalty Corp. (Origin Ian is a finance leader with more than 25 years of Andr
Slide 11: Proven Board of Directors
Proven Board of Directors Marc Lustig Bill Petron Chairman and Chief Executive Officer Lead Director Mr. Petron is a highly respected entrepreneur with a diverse background in manufacturing, logistics and medical cannabis. Mr. Petron has founded, grown and sold several successful global businesses.
Slide 12: Summary Financial Information
Summary Financial Information Summary Financials As of Q3 2023 Three months ended (000’s) September 30 2023 September 30 2022 Revenue $ 352 $ 475 For further detailed information and analysis, please see the financial statements and management's discussion and Adjusted EBITDA (Loss) $ (1,370) $ (2,4
Slide 13: Capacity at a Global Scale
Capacity at a Global Scale 3.6 M The scale of both cultivation and extraction capacity puts Cultivation Area PharmaCielo on par with the world’s leading producers of medical 2.7 M (SQUARE FEET) cannabis flower and extracts. 1.5 M 1.3 M Market Cap as of February 12 th, 2024 0.75 M $5.3B $ 1.9B Extract
Slide 14: The World’s Partner in Medicinal Cannabis
The World’s Partner in Medicinal Cannabis TSXV: PCLO, OTCQX: PCLOF | Feb 2024